VistaGen Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 40
- Market Cap
- $95.5M
- Website
- http://www.vistagen.com
- Introduction
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
- Conditions
- Social Anxiety Disorder
- Interventions
- Drug: Fasedienol Nasal Spray - Placebo Nasal SprayDrug: Fasedienol Nasal Spray - Fasedienol Nasal SprayDrug: Placebo Nasal Spray - Placebo Nasal Spray
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06809179
- Locations
- 🇺🇸
Vistagen Clinical Site, Plano, Texas, United States
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
- Conditions
- Social Anxiety Disorder (SAD)
- Interventions
- Drug: Placebo Nasal Spray
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT06615557
- Locations
- 🇺🇸
Vistagen Clinical Site, Houston, Texas, United States
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
- Conditions
- Social Anxiety Disorder
- Interventions
- Drug: Placebo Nasal Spray
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT06358651
- Locations
- 🇺🇸
Vistagen Clinical Site, Everett, Washington, United States
AV-101 Alone and in Combination With Probenecid in Healthy Subjects
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05280054
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Glendale, California, United States
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 483
- Registration Number
- NCT05030350
- Locations
- 🇺🇸
VistaGen Investigational Site, Bellevue, Washington, United States
- Prev
- 1
- 2
- 3
- Next
News
Major Depressive Disorder Pipeline Advances with 75+ Companies Developing Novel Therapies
A comprehensive pipeline report reveals over 75 companies are developing innovative treatments for major depressive disorder, with several promising candidates advancing through Phase III trials.
VistaGen's Anxiety Drug Trials Maintain Stifel's Optimism
VistaGen Therapeutics is progressing with Phase 3 clinical trials for fasedienol, a drug candidate for Social Anxiety Disorder (SAD).
VistaGen's Fasedienol Shows Promise in Phase 3 Trials for Social Anxiety Disorder
VistaGen's Phase 3 trials for fasedienol in acute social anxiety disorder are progressing, with PALISADE-4 active and results expected from PALISADE-3 and PALISADE-4 in 2025.